Updated Results Show Ongoing Treatment-Free Remission in CML Trial
Updated results from ENESTop show patients with CML remain in treatment-free remission after stopping nilotinib.
Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation.
Long-Awaited Results of Isatuximab Combo in R/R Myeloma Presented
Researchers evaluated survival and infusion time with combination isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide plus low-dose dexamethasone alone in relapsed or refractory multiple myeloma.
Long-Term Results of Ofatumumab + Chlorambucil in CLL Presented
Five-year follow-up of the phase III COMPLEMENT 1 study focused on the efficacy with respect to overall and progression-free survival.
Subcutaneous vs Intravenous Daratumumab: Which Is Better for R/R Myeloma?
The COLUMBA trial examined the efficacy, number of infusion-related reactions, and administration time for SC vs IV daratumumab in R/R multiple myeloma.
Benefits With Gilteritinib for AML Were Maintained, Regardless of Co-Mutations
The survival benefit observed with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia in the ADMIRAL trial was maintained regardless of the presence of several common co-mutations.
Anti-BCMA BiTE Immunotherapy: An Option for R/R Multiple Myeloma?
Data from the first-in-human study of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, were presented at ASCO 2019.
Largest Analysis to Date Examines Link Between Smoking and Outcomes in Acute Myeloid Leukemia
Data were presented at ASCO 2019 on the link between current and former smoking on treatment outcomes in AML in treatment-naive patients.
Promising CAR T-Cell Agent for ALL Enters Phase II With Revised AE Management Protocol
A phase I study of a CAR T-cell therapy showed success in refining cell dosing and adverse event management protocols in patients with relapsed/refractory ALL.
Daratumumab + European Standard Yields Clinical Benefit in Transplant Eligible, Newly Diagnosed Myeloma
New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.
Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in relapsed/refractory large B-cell lymphoma.
Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in relapsed/refractory indolent non-Hodgkin lymphoma.
Location and Insurance Matter When It Comes to Survival in Multiple Myeloma
Research presented at ASCO 2019 posited that multiple socioeconomic factors make a real difference in overall survival.
BCMA-Targeting CAR T-Cell Tx Effective in R/R MM
CAR T-cell therapy with bb2121 induced deep, long-lasting responses in patients with heavily pretreated MM.
Most Breast Implant–Associated Lymphomas Have Indolent Clinical Course
A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course.
Ibrutinib/Rituximab Yields Prolonged PFS in Waldenström Macroglobulinemia
In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.
Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia.
Durable Responses in R/R DLBCL With CAR-T Product Lisocabtagene Maraleucel
In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.
Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.
Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.
Personalized Molecular Phenotyping May Help Secondary AML
This approach may lead to better understanding of risk-mitigation strategies, and perhaps better outcomes in patients with secondary AML.
Unconventional Strategies May Be Required for TP53-Mutated AML
Unconventional strategies and targeted therapeutics may be required to overcome the adverse risks associated with TP53-mutated AML.
Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.
Cellular Therapies for Multiple Myeloma: A Paradigm Shift
Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn’s Adam Cohen at ASCO 2018.
Genomics Revolution Taking Off in Multiple Myeloma
Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma.
ASCO Preview: Lymphoma Presentation Highlights
Joshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.
Targeting IDH in Acute Myeloid Leukemia
This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.
Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.
Enasidenib Promising in IDH2-Mutant Relapsed Acute Myeloid Leukemia
The novel IDH2-inhibitor enasidenib was well tolerated and offered durable responses in a phase I trial of relapsed or refractory acute myeloid leukemia patients with an IDH2 mutation.
Carfilzomib Associated With Cardiotoxicity Risk in Multiple Myeloma
Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.